PINK1

PTEN-induced kinase 1 (PINK1) is a mitochondrial serine/threonine-protein kinase encoded by the PINK1 gene.

PINK1
Identifiers
Aliases	PINK1, BRPK, PARK6, PTEN induced putative kinase 1, PTEN induced kinase 1
External IDs	OMIM: 608309; MGI: 1916193; HomoloGene: 32672; GeneCards: PINK1; OMA:PINK1 - orthologs
Gene location (Human) Chr. Chromosome 1 (human) Band 1p36.12 Start 20,633,458 bp End 20,651,511 bp
Gene location (Mouse) Chr. Chromosome 4 (mouse) Band 4|4 D3 Start 138,040,720 bp End 138,053,618 bp
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in tendon of biceps brachii glutes gastrocnemius muscle right frontal lobe prefrontal cortex Amygdala muscle of thigh apex of heart putamen nucleus accumbens Top expressed in muscle of thigh myocardium of ventricle intercostal muscle sciatic nerve digastric muscle triceps brachii muscle ankle sternocleidomastoid muscle temporal muscle extraocular muscle More reference expression data BioGPS More reference expression data
Gene ontology Molecular function C3HC4-type RING finger domain binding kinase activity ATP binding protein kinase activity metal ion binding protein serine/threonine kinase activity calcium-dependent protein kinase activity peptidase activator activity magnesium ion binding transferase activity protease binding protein binding nucleotide binding protein kinase B binding ubiquitin protein ligase binding Cellular component cytoplasm cytosol membrane mitochondrial intermembrane space mitochondrion perinuclear region of cytoplasm cytoskeleton nucleus Lewy body integral component of mitochondrial outer membrane mitochondrial outer membrane chromatin TORC2 complex integral component of membrane ubiquitin ligase complex mitochondrial outer membrane translocase complex astrocyte projection axon cell body mitochondrial inner membrane growth cone Biological process negative regulation of neuron apoptotic process positive regulation of mitophagy in response to mitochondrial depolarization positive regulation of free ubiquitin chain polymerization regulation of protein ubiquitination cellular response to toxic substance positive regulation of catecholamine secretion regulation of synaptic vesicle transport positive regulation of translation protein phosphorylation positive regulation of dopamine secretion macroautophagy regulation of protein-containing complex assembly cellular response to hypoxia negative regulation of autophagosome assembly positive regulation of protein kinase B signaling positive regulation of protein dephosphorylation ubiquitin-dependent protein catabolic process peptidyl-serine autophosphorylation regulation of neuron apoptotic process response to oxidative stress negative regulation of gene expression positive regulation of peptidyl-serine phosphorylation negative regulation of mitochondrial fission positive regulation of mitochondrial electron transport, NADH to ubiquinone positive regulation of macroautophagy regulation of autophagy of mitochondrion positive regulation of ubiquitin-protein transferase activity negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway protein ubiquitination negative regulation of oxidative stress-induced cell death negative regulation of intrinsic apoptotic signaling pathway in response to hydrogen peroxide positive regulation of synaptic transmission, dopaminergic negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway regulation of oxidative phosphorylation regulation of mitochondrion organization regulation of hydrogen peroxide metabolic process negative regulation of oxidative stress-induced neuron death protein stabilization mitochondrion organization positive regulation of DNA-binding transcription factor activity negative regulation of autophagy of mitochondrion regulation of reactive oxygen species metabolic process positive regulation of ATP biosynthetic process maintenance of protein location in mitochondrion regulation of protein targeting to mitochondrion positive regulation of release of cytochrome c from mitochondria respiratory electron transport chain positive regulation of protein ubiquitination regulation of proteasomal protein catabolic process activation of protein kinase B activity intracellular signal transduction negative regulation of macroautophagy positive regulation of protein targeting to mitochondrion positive regulation of cristae formation positive regulation of peptidase activity TORC2 signaling regulation of mitochondrial membrane potential autophagy negative regulation of JNK cascade establishment of protein localization to mitochondrion autophagy of mitochondrion peptidyl-serine phosphorylation positive regulation of I-kappaB kinase/NF-kappaB signaling cellular response to oxidative stress negative regulation of reactive oxygen species metabolic process negative regulation of apoptotic process positive regulation of protein phosphorylation positive regulation of histone deacetylase activity mitochondrion to lysosome transport regulation of cellular response to oxidative stress response to ischemia positive regulation of mitochondrial fission positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization cellular response to hydrogen sulfide phosphorylation negative regulation of neuron death positive regulation of NMDA glutamate receptor activity negative regulation of intrinsic apoptotic signaling pathway Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 65018 68943 Ensembl ENSG00000158828 ENSMUSG00000028756 UniProt Q9BXM7 Q99MQ3 RefSeq (mRNA) NM_032409 NM_026880 RefSeq (protein) NP_115785 NP_081156 Location (UCSC) Chr 1: 20.63 – 20.65 Mb Chr 4: 138.04 – 138.05 Mb PubMed search
Wikidata
View/Edit Human View/Edit Mouse

It is thought to protect cells from stress-induced mitochondrial dysfunction. PINK1 activity causes the parkin protein to bind to depolarized mitochondria to induce autophagy of those mitochondria. PINK1 is processed by healthy mitochondria and released to trigger neuron differentiation. Mutations in this gene cause one form of autosomal recessive early-onset Parkinson's disease.

Structure

PINK1 is synthesized as a 63000 Da protein which is often cleaved by PARL, between the 103-Alanine and the 104-Phenylalanine residues, into a 53000 Da fragment. PINK1 contains an N-terminal mitochondrial localization sequence, a putative transmembrane sequence, a Ser/Thr kinase domain, and a C-terminal regulatory sequence. The protein has been found to localize to the outer membrane of mitochondria, but can also be found throughout the cytosol. Experiments suggest the Ser/Thr kinase domain faces outward toward the cytosol, indicating a possible point of interaction with parkin.

The structure of PINK1 has been solved and shows how the protein binds and phosphorylates its substrate ubiquitin.

Function

PINK1 is intimately involved with mitochondrial quality control by identifying damaged mitochondria and targeting specific mitochondria for degradation. Healthy mitochondria maintain a membrane potential that can be used to import PINK1 into the inner membrane where it is cleaved by PARL and cleared from the outer membrane. Severely damaged mitochondria lack sufficient membrane potential to import PINK1, which then accumulates on the outer membrane. PINK1 then recruits parkin to target the damaged mitochondria for degradation through autophagy. Due to the presence of PINK1 throughout the cytoplasm, it has been suggested that PINK1 functions as a "scout" to probe for damaged mitochondria.

Damaged mitochondria is being recognized by PINK1. PINK1 builds up on the outer membrane of the mitochondria and recruits parkin. The PINK1/parkin pathway then designates the mitochondria for degradation by lysosomes.

Healthy mitochondria can import PINK1 where it is subsequently cleaved by PARL. This prevents any buildup of PINK1 and parkin is not recruited to the mitochondria.

PINK1 may also control mitochondria quality through mitochondrial fission. Through mitochondrial fission, a number of daughter mitochondria are created, often with an uneven distribution in membrane potential. Mitochondria with a strong, healthy membrane potential were more likely to undergo fusion than mitochondria with low membrane potential. Interference with the mitochondrial fission pathway led to an increase in oxidized proteins and a decrease in respiration. Without PINK1, parkin cannot efficiently localize to damaged mitochondria, while an over-expression of PINK1 causes parkin to localize to even healthy mitochondria. Furthermore, mutations in both Drp1, a mitochondrial fission factor, and PINK1 were fatal in Drosophila models. However, an over-expression of Drp1 could rescue subjects deficient in PINK1 or parkin, suggesting mitochondrial fission initiated by Drp1 recreates the same effects of the PINK1/parkin pathway.

In addition to mitochondrial fission, PINK1 has been implicated in mitochondrial motility. The accumulation of PINK1 and recruitment of parkin targets a mitochondrion for degradation, and PINK1 may serve to enhance degradation rates by arresting mitochondrial motility. Over-expression of PINK1 produced similar effects to silencing Miro, a protein closely associated with mitochondrial migration.

Another mechanism of mitochondrial quality control may arise through mitochondria-derived vesicles. Oxidative stress in mitochondria can produce potentially harmful compounds including improperly folded proteins or reactive oxygen species. PINK1 has been shown to facilitate the creation of mitochondria-derived vesicles which can separate reactive oxygen species and shuttle them toward lysosomes for degradation.

Disease relevance

Parkinson's disease is often characterized by the degeneration of dopaminergic neurons and associated with the build-up of improperly folded proteins and Lewy bodies. Mutations in the PINK1 protein have been shown to lead to a build-up of such improperly folded proteins in the mitochondria of both fly and human cells. Specifically, mutations in the serine/threonine kinase domain have been found in a number of Parkinson's patients where PINK1 fails to protect against stress-induced mitochondrial dysfunction and apoptosis.

Pharmacological manipulation

To date, there have been few reports of small molecules that activate PINK1 and their promise as potential treatments for Parkinson's disease. The first report appeared in 2013 when Kevan Shokat and his team from UCSF identified a nucleobase called kinetin as an activator of PINK1. Subsequently, it was shown by others that the nucleoside derivative of kinetin, i.e. kinetin riboside, exhibited significant activation of PINK1 in cells. Additionally, the monophosphate prodrugs of kinetin riboside, ProTides, also showed activation of PINK1. In December 2017, niclosamide, an anthelmintic drug, was identified as a potent activator of PINK1 in cells and in neurons.

Further reading

• Heutink P (2006). "PINK-1 and DJ-1 — new genes for autosomal recessive Parkinson's disease". Parkinson's Disease and Related Disorders. Journal of Neural Transmission. Supplementa. Vol. 70. pp. 215–9. doi:10.1007/978-3-211-45295-0_33. ISBN 978-3-211-28927-3. PMID 17017532. {{cite book}}: |journal= ignored (help)
• Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, Albanese A, Wood NW (2001). "Localization of a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism, PARK6, on Human Chromosome 1p35-p36". Am. J. Hum. Genet. 68 (4): 895–900. doi:10.1086/319522. PMC 1275643. PMID 11254447.
• Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, Piccini P (2002). "Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study". Ann. Neurol. 52 (6): 849–53. doi:10.1002/ana.10417. PMID 12447943. S2CID 9275470.
• Bonifati V, Dekker MC, Vanacore N, Fabbrini G, Squitieri F, Marconi R, Antonini A, Brustenghi P, Dalla Libera A, De Mari M, Stocchi F, Montagna P, Gallai V, Rizzu P, van Swieten JC, Oostra B, van Duijn CM, Meco G, Heutink P (2003). "Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7". Neurol. Sci. 23 (Suppl 2): S59–60. doi:10.1007/s100720200069. PMID 12548343. S2CID 13625056.
• Valente EM, Brancati F, Caputo V, Graham EA, Davis MB, Ferraris A, Breteler MM, Gasser T, Bonifati V, Bentivoglio AR, De Michele G, Dürr A, Cortelli P, Filla A, Meco G, Oostra BA, Brice A, Albanese A, Dallapiccola B, Wood NW (2003). "PARK6 is a common cause of familial parkinsonism". Neurol. Sci. 23 (Suppl 2): S117–8. doi:10.1007/s100720200097. PMID 12548371. S2CID 21061495.
• Nakajima A, Kataoka K, Hong M, Sakaguchi M, Huh NH (2004). "BRPK, a novel protein kinase showing increased expression in mouse cancer cell lines with higher metastatic potential". Cancer Lett. 201 (2): 195–201. doi:10.1016/S0304-3835(03)00443-9. PMID 14607334.
• Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004). "Hereditary early-onset Parkinson's disease caused by mutations in PINK1". Science. 304 (5674): 1158–60. Bibcode:2004Sci...304.1158V. doi:10.1126/science.1096284. PMID 15087508. S2CID 33630092.
• Healy DG, Abou-Sleiman PM, Ahmadi KR, Muqit MM, Bhatia KP, Quinn NP, Lees AJ, Latchmann DS, Goldstein DB, Wood NW (2004). "The gene responsible for PARK6 Parkinson's disease, PINK1, does not influence common forms of parkinsonism". Ann. Neurol. 56 (3): 329–35. doi:10.1002/ana.20206. PMID 15349859. S2CID 1235813.
• Hatano Y, Li Y, Sato K, Asakawa S, Yamamura Y, Tomiyama H, Yoshino H, Asahina M, Kobayashi S, Hassin-Baer S, Lu CS, Ng AR, Rosales RL, Shimizu N, Toda T, Mizuno Y, Hattori N (2004). "Novel PINK1 mutations in early-onset parkinsonism". Ann. Neurol. 56 (3): 424–7. doi:10.1002/ana.20251. PMID 15349870. S2CID 10853835.
• Hatano Y, Sato K, Elibol B, Yoshino H, Yamamura Y, Bonifati V, Shinotoh H, Asahina M, Kobayashi S, Ng AR, Rosales RL, Hassin-Baer S, Shinar Y, Lu CS, Chang HC, Wu-Chou YH, Ataç FB, Kobayashi T, Toda T, Mizuno Y, Hattori N (2004). "PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations". Neurology. 63 (8): 1482–5. doi:10.1212/01.wnl.0000142258.29304.fe. PMID 15505170. S2CID 13480500.
• Healy DG, Abou-Sleiman PM, Gibson JM, Ross OA, Jain S, Gandhi S, Gosal D, Muqit MM, Wood NW, Lynch T (2006). "PINK1 (PARK6) associated Parkinson disease in Ireland". Neurology. 63 (8): 1486–8. doi:10.1212/01.wnl.0000142089.38301.8e. PMID 15505171. S2CID 24418905.
• Rogaeva E, Johnson J, Lang AE, Gulick C, Gwinn-Hardy K, Kawarai T, Sato C, Morgan A, Werner J, Nussbaum R, Petit A, Okun MS, McInerney A, Mandel R, Groen JL, Fernandez HH, Postuma R, Foote KD, Salehi-Rad S, Liang Y, Reimsnider S, Tandon A, Hardy J, St George-Hyslop P, Singleton AB (2005). "Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease". Archives of Neurology. 61 (12): 1898–904. doi:10.1001/archneur.61.12.1898. PMID 15596610.
• Beilina A, Van Der Brug M, Ahmad R, Kesavapany S, Miller DW, Petsko GA, Cookson MR (2005). "Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability". Proc. Natl. Acad. Sci. U.S.A. 102 (16): 5703–8. Bibcode:2005PNAS..102.5703B. doi:10.1073/pnas.0500617102. PMC 556294. PMID 15824318.
• Deng H, Le WD, Zhang X, Pan TH, Jankovic J (2005). "G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients". Acta Neurol. Scand. 111 (6): 351–2. doi:10.1111/j.1600-0404.2005.00383.x. PMID 15876334. S2CID 10669009.
• Li Y, Tomiyama H, Sato K, Hatano Y, Yoshino H, Atsumi M, Kitaguchi M, Sasaki S, Kawaguchi S, Miyajima H, Toda T, Mizuno Y, Hattori N (2005). "Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism". Neurology. 64 (11): 1955–7. doi:10.1212/01.WNL.0000164009.36740.4E. PMID 15955953. S2CID 46024206.

External links

• GeneReviews/NCBI/NIH/UW entry on PINK1 Type of Young-Onset Parkinson Disease